Featured Research

from universities, journals, and other organizations

Lenalidomide offers an effective alternative treatment for cutaneus lupus erythematosus, study suggests

Date:
December 7, 2012
Source:
BioMed Central Limited
Summary:
Although rare there are several treatments available for cutaneus lupus erythematosus (CLE). However other options are needed for people who do not respond to medication or relapse. A new study into the thalidomide derivative lenalidomide shows that treatment with lenalidomide is safe, with patients seeing an improvement in as little as two weeks.

Although rare there are several treatments available for cutaneus lupus erythematosus (CLE). However other options are needed for people who do not respond to medication or relapse. A new study into the thalidomide derivative lenalidomide, published December 7 in BioMed Central's open access journal Arthritis Research & Therapy, shows that treatment with lenalidomide is safe, with patients seeing an improvement in as little as two weeks.

Related Articles


There have been several small scale clinical studies into the use of thalidomide for CLE for the third of patients which do not respond to the standard therapy including steroids, antimalarials and immunosuppressive agents. Although thalidomide has a bad press because of its effects on embryonic development, properly administered it is an effective alternative treatment for several types of cancer and inflammatory conditions, albeit with severe side effects which can limit continuous use.

Lenalidomide has been suggested as a more potent, but less toxic, alternative, and previous studies on a small number of patients have had encouraging results. In order to examine the efficacy of lenalidomide more thoroughly researchers from Vall d΄Hebron University Hospital Research Institute, Spain, initiated a phase II clinical study, following 15 people with CLE, for between 7 and 30 months, all of which had previously not responded to traditional therapy.

All but one of the people involved in the trial saw clinical improvement and most of these (86%) had complete response, reaching a CLASI score of 0. Three quarters of people who improved with lenalidomide relapsed within 2-8 weeks of the medication being stopped or reduced.

In this study side effects were minor. Only two people reported side effects -- although for one person their gastrointestinal symptoms meant that they stopped taking lenalidomide after one week. For both people the side effects disappeared once they stopped taking the drug.

Dr Josep Ordi-Ros, lead author of the study, explained, "The small impact of side effects in this study compared to others, may be due to the low dose of lenalidomide used. We also did not see any of the systemic lupus erythematosus (SLE) effects reported in smaller studies, even after 15 months of follow up. Nevertheless this regime was very effective in reducing disfigurement due to CLE and was similar in effect to thalidomide but with lower toxicity."

While a phase II study is still comparatively small, its long length and the significant number of patients studied provides a firm basis for larger scale, randomized, clinical trials, and provides a more positive outlook for the use of lenalidomide in the treatment of CLE.


Story Source:

The above story is based on materials provided by BioMed Central Limited. Note: Materials may be edited for content and length.


Journal Reference:

  1. Josefina Cortes-Hernandez, Gabriela Avila, Miquel Vilardell-Tarres, Josep Ordi-Ros. Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus. Arthritis Research & Therapy, 2012; 14 (6): R265 DOI: 10.1186/ar4111

Cite This Page:

BioMed Central Limited. "Lenalidomide offers an effective alternative treatment for cutaneus lupus erythematosus, study suggests." ScienceDaily. ScienceDaily, 7 December 2012. <www.sciencedaily.com/releases/2012/12/121206203150.htm>.
BioMed Central Limited. (2012, December 7). Lenalidomide offers an effective alternative treatment for cutaneus lupus erythematosus, study suggests. ScienceDaily. Retrieved March 29, 2015 from www.sciencedaily.com/releases/2012/12/121206203150.htm
BioMed Central Limited. "Lenalidomide offers an effective alternative treatment for cutaneus lupus erythematosus, study suggests." ScienceDaily. www.sciencedaily.com/releases/2012/12/121206203150.htm (accessed March 29, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Sunday, March 29, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) — A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com
WH Plan to Fight Antibiotic-Resistant Germs

WH Plan to Fight Antibiotic-Resistant Germs

AP (Mar. 27, 2015) — The White House on Friday announced a five-year plan to fight the threat posed by antibiotic-resistant bacteria amid fears that once-treatable germs could become deadly. (March 27) Video provided by AP
Powered by NewsLook.com
House Ready to Pass Medicare Doc Bill

House Ready to Pass Medicare Doc Bill

AP (Mar. 26, 2015) — In rare bipartisan harmony, congressional leaders pushed a $214 billion bill permanently blocking physician Medicare cuts toward House passage Thursday, moving lawmakers closer to resolving a problem that has plagued them for years. (March 26) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins